Delivery Order HHSN261201500003I-75N91018F00077
Award Date
9/24/18
Potential Completion Date
8/29/29
Potential Value
$54M
Federal Agency
National Cancer Institute
Awardee
Leidos Biomedical Research Inc.
Ultimate Awardee
Leidos Holdings, Inc.
NAICS Category
561210 - Facilities Support Services
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Fort Detrick, MD 21702, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $12,149,451.00 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the elaboration and use of syngeneic pre-clinical models for cancer drug development, with a period of performance through September 15, 2026. This is not a set-aside contract. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for...
This is a $2,528,739 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is part of the NCI's Cancer Data Ecosystem program and has an ultimate completion date of April 30, 2026. The contract does not have a set-aside designation. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing a wide range of...
This is a delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $1,247,433.00 cost-plus-fixed-fee contract is for the administration of a GD2 CAR-T cell therapy clinical trial site and cell distribution logistics. The contract has an ultimate completion date of September 27, 2025. There is no set-aside designation indicated. Leidos Biomedical...
This is a $5,659,274.00 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for characterizing the mechanism of action of investigational and approved cancer agents. It has an ultimate completion date of September 21, 2028. The contract is not set aside for any socioeconomic category. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center...
This is a $4,696,754.00 cost-plus-fixed-fee delivery order awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for GD2 CAR T MANUFACTURING services, with a period of performance through September 29, 2024. As a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, Leidos Biomedical Research provides comprehensive biomedical research and facilities support services, including...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the NCI Federally Funded Research and Development Center (FFRDC) and has a ceiling value of $6,371,084.00. The contract period of performance runs through November 13, 2025. Leidos Biomedical Research Inc. provides a range of biomedical research and facilities support services to federal agencies, with a...
This is a Cost Plus Fixed Fee Delivery Order contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract has a ceiling value of $1,361,419.00 and is for insilico and ex-vivo immunogenicity analysis of NCATS gene therapy tests. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing a broad...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $5,418,352.00 cost-plus-fixed-fee delivery order contract to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., for antibody production and characterization. This work is being performed at Fort Detrick, Maryland. Leidos Biomedical Research has extensive experience supporting biomedical research programs at the National Institutes of Health, including the National...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a cost-plus-fixed-fee delivery order contract worth up to $3,332,886.00 to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the identification and delivery of clinical drug candidates, with a completion date of September 24, 2025. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) that provides...
This is a $4,490,899.23 cost-no-fee Delivery Order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is to develop and implement capacity to monitor circulating tumor nucleic acid, with a period of performance ending on September 25, 2020. This contract is not associated with a set-aside program. Leidos Biomedical Research Inc. operates as a...